Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion
NCT ID: NCT02694198
Last Updated: 2016-05-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
135 participants
OBSERVATIONAL
2015-09-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Pregnancy Ultrasound Measurements and Prediction of First Trimester Pregnancy Loss.
NCT06540092
Biochemical Versus Ultrasound Findings as Predictors of Fetal Loss in Cases of First Trimester Threatened Miscarriage
NCT03797508
the Insulin Resistance in Recurrent Miscarriage IN RECURRENT ABORTION
NCT02088424
Factors Associated With Pregnancy Loss in IVF Women
NCT02383394
Surgical Evacuation of Abortion Under Ultrasonographic Guide
NCT02580175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Before entering the study, the purpose of this work will be clearly explained and verbal consent will be obtained from all patients enrolled in the study along with routine written informed consent as governed by the hospital rules.
All participants will be subjected to:
1. History taking:
1. Personal history: age and special habits
2. Obstetric history (parity, history of abortions, previous cerculage and preterm labor). Gestational Age will be assigned by means of a combination of menstrual dating and ultrasonographic evaluation.
3. Past medical history (hypersensitivity to misoprostol, chronic adrenal insufficiency and inherited porphyrias).
4. Past history of previous cesarean section or other operations as hysterotomy and myomectomy.
2. Examination:
1. General examination: blood pressure, pulse, temperature, body weight.
2. Abdominal examination: fundal level, presence of scar of previous operations, uterine contractions.
3. Investigations:
1. Laboratory: complete blood count, c-reactive protein titre, blood group.
2. Pelvic ultrasound: to assess fetal viability, amount of liquor, gestational age, position of the placenta.
4. Assessment of vaginal fetal fibronectin:
All Patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the fetal fibronectin kit will be used to collect a sample of secretions from the posterior fornix. The sample will be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2ml) is not found, vagina will be washed with 2ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
According to Ain Shams University Maternity Hospital protocol, termination of pregnancy will be conducted as an inpatient procedure. Termination of pregnancy will be performed using misoprostol tablets (MisotacĀ® Sigma 200 mcg per tablet). Misoprostol tablets will be introduced by vaginal routes initially (total 800 mcg). Following the initial dose, 2 misoprostol tablets (400 mcg) will be inserted into the vagina every 4 hours to a maximum of four doses. If the woman does not have adequate contractions, within 8 hours following the last dose, the same regimen will be repeated over the following 24 hours without the loading dose.
The induction to expulsion period will be defined as the time from commencement of misoprostol until fetal expulsion without exerting any fetal traction by caregiver. After expulsion of the fetus, the patients will receive 30 units of oxytocin on 500 cc Ringer solution slowly by intravenous infusion over 30 minutes for expulsion of the placenta. Surgical evacuation will be done when indicated.
The kits used to measure level of fetal fibronectin in vaginal sample (ZYMUTEST Fibronectin kits) were provided from Hyphen BioMed corporation , France. The ZYMUTEST Fibronectin kit is an one-step enzyme immuno-assay for measuring human Fibronectin in plasma, or in any fluid where fibronectin can be present.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fetal fibronectin measurement
All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 14-24 weeks gestation..
* Missed miscarriage
Exclusion Criteria
* History of previous cesarean section and other uterine surgeries as hysterotomy and myomectomy.
* Inevitable abortion.
* Placenta covering internal os.
* History of any cervical surgery as cervical amputation, cauterization or dilatation.
* Premature rupture of membranes.
* Any vaginal bleeding.
* Contraindications for misoprostol as hypersensitivity to misoprostol, chronic adrenal insufficiency and inherited porphyrias.
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams Maternity Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amr Ahmed Mahmoud Riad
Lecturer of obstetrics and gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams maternity hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
fetal fibronectin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.